TY - JOUR
T1 - New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies
T2 - do they have a role in bridging, consolidating or conditioning transplantation treatment?
AU - Patriarca, Francesca
AU - Giaccone, Luisa
AU - Onida, Francesco
AU - Castagna, Luca
AU - Sarina, Barbara
AU - Montefusco, Vittorio
AU - Mussetti, Alberto
AU - Mordini, Nicola
AU - Maino, Elena
AU - Greco, Raffaella
AU - Peccatori, Jacopo
AU - Festuccia, Moreno
AU - Zaja, Francesco
AU - Volpetti, Stefano
AU - Risitano, Antonio
AU - Bassan, Renato
AU - Corradini, Paolo
AU - Ciceri, Fabio
AU - Fanin, Renato
AU - Baccarani, Michele
AU - Rambaldi, Alessandro
AU - Bonifazi, Francesca
AU - Bruno, Benedetto
PY - 2017/7
Y1 - 2017/7
N2 - INTRODUCTION: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to 'smartly' combine 'targeted drugs and cell therapies' in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.
AB - INTRODUCTION: Novel targeted therapies and monoclonal antibodies can be combined with allogeneic stem cell transplantation (allo-SCT) at different time-points: 1) before the transplant to reduce tumour burden, 2) as part of the conditioning in place of or in addition to conventional agents 3) after the transplant to allow long-term disease control. Areas covered: This review focuses on the current integration of new drugs with allo-SCT for the treatment of major hematological malignancies for which allo-SCT has been a widely-adopted therapy. Expert opinion: After having been used as single agent salvage treatments in relapsed patients after allo-SCT or in combination with donor lymphocyte infusions, many new drugs have also been safely employed before allo-SCT as a bridge to transplantation or after it as planned consolidation/maintenance. This era of new drugs has opened new important opportunities to 'smartly' combine 'targeted drugs and cell therapies' in new treatment paradigms that may lead to higher cure rates or longer disease control in patients with hematological malignancies.
KW - Antibodies, Monoclonal
KW - Antineoplastic Agents
KW - Graft vs Host Disease
KW - Hematologic Neoplasms
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Protein Kinase Inhibitors
KW - Salvage Therapy
KW - Transplantation, Homologous
KW - Journal Article
KW - Review
U2 - 10.1080/14712598.2017.1324567
DO - 10.1080/14712598.2017.1324567
M3 - Review article
C2 - 28506131
VL - 17
SP - 821
EP - 836
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 7
ER -